Indicated for ulcerative colitis and rheumatoid arthritis to manage inflammation and support tissue preservation.
Mechanism of Action
Sulfasalazine is cleaved by colonic bacteria into sulfapyridine and mesalamine. Mesalamine acts locally to inhibit prostaglandin synthesis in the gut, while sulfapyridine provides systemic immunomodulatory effects for joint disease.
Route of Administration
Oral
Onset Time
4–12 weeks
Duration
6–10 hours (half-life)
Contraindications
Hypersensitivity to salicylates, Hypersensitivity to sulfonamides, Intestinal obstruction, Urinary obstruction, Porphyria
Severe Adverse Events
Agranulocytosis, Hepatotoxicity, Stevens-johnson syndrome — requires immediate medical attention
Common Side Effects
Nausea, Headache, Anorexia
Uncommon Side Effects
Rash, Abdominal discomfort, Orange urine
Drug Interactions
Alcohol, Digoxin, Folic Acid, Warfarin, Iron Supplements
Pregnancy Safety Warnings
FDA Category B: Use with caution; monitor folate levels. Breastfeeding: Excreted in milk; compatible with caution.
Age Restrictions
Safety and efficacy established in pediatric patients six years and older.
Information related to Sulfasalazine is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
